Aclaris Therapeutics, INC 8-K filings

Aclaris Therapeutics has amended its at-the-market sales agreement, allowing for continued offering of common stock through sales agents.

Aclaris Therapeutics announced its second quarter 2026 financial results, highlighting positive Phase 1a trial data for ATI-052 and reaffirming timelines for key clinical readouts, with a cash runway extending through 2028.

Aclaris Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and approval of executive compensation.

Aclaris Therapeutics reported Q1 2026 financial results, highlighting positive Phase 1a data for ATI-052 and confirming a cash runway through 2028.

Aclaris Therapeutics announces positive Phase 1a results for ATI-052, supporting potential for extended dosing, and selects lichen planus as the lead indication for ATI-2138.

Aclaris Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting positive interim Phase 1a results for ATI-052 and progress across its immuno-inflammatory disease pipeline.

Aclaris Therapeutics, Inc. updated its corporate overview presentation, showcasing advancements in its inflammation and immunology pipeline, including positive interim clinical data for ATI-052 and ongoing trials for Bosakitug and ATI-2138.

Aclaris Therapeutics announced positive interim Phase 1a results for its bispecific antibody ATI-052, showing a favorable safety profile, best-in-class pharmacokinetic profile, and strong pharmacodynamic effects, supporting potential quarterly dosing and accelerated clinical development.

Aclaris Therapeutics announced its third quarter 2025 financial results and provided a corporate update, highlighting positive Phase 2a trial data for ATI-2138 and a strong cash runway into the second half of 2028.

Aclaris Therapeutics hosted an R&D Day to showcase its pipeline of immuno-inflammatory disease therapies, highlighting three clinical programs in 2025 and four anticipated in 2026, supported by a cash runway into H2 2028.

Aclaris Therapeutics announced its second quarter 2025 financial results, highlighting positive clinical trial data for ATI-2138, advancement of Bosakitug and ATI-052, and a strong cash runway into H2 2028.

Aclaris Therapeutics announced positive top-line results from its Phase 2a clinical trial of ATI-2138 for moderate-to-severe atopic dermatitis, demonstrating a favorable tolerability profile and clinically meaningful efficacy.

Aclaris Therapeutics, Inc. updated its corporate overview presentation, showcasing a robust immunology pipeline with promising clinical data for its drug candidates and an extended cash runway through the first half of 2028.

Aclaris Therapeutics, Inc. announced that its stockholders approved the 2025 Equity Incentive Plan and an amendment to increase the authorized common stock from 200 million to 400 million shares at the company's 2025 annual meeting.

Aclaris Therapeutics announces its Q1 2025 financial results, highlighting progress in its immuno-inflammatory pipeline and extending its cash runway through the first half of 2028.

Aclaris Therapeutics announces its Q4 and full year 2024 financial results, highlighting a transformative year with multiple clinical catalysts expected in 2025 and a cash runway into 2028.

Aclaris Therapeutics provides a corporate overview, emphasizing its pipeline of immuno-inflammatory disease therapeutics and a cash runway extending into 2028.

Aclaris Therapeutics has secured an exclusive global license agreement with Biosion, adding two potential best-in-class biologics to its pipeline and expanding its leadership team.

Aclaris Therapeutics announced its third quarter 2024 financial results, highlighted by the first patient dosed in the Phase 2a trial of ATI-2138 for atopic dermatitis and a robust cash position.

Aclaris Therapeutics announced its second quarter 2024 financial results, highlighted by a strengthened balance sheet and progress in clinical development programs.

Aclaris Therapeutics has sold a portion of its future royalty payments and milestone rights for Olumiant to OMERS for an upfront payment of $26.5 million, with potential for an additional $5 million based on sales milestones.

Aclaris Therapeutics held its 2024 annual meeting where shareholders elected two directors, approved executive compensation, and ratified the appointment of PricewaterhouseCoopers as auditor.

Aclaris Therapeutics reported its Q1 2024 financial results, highlighted by a net loss of $16.9 million and the advancement of ATI-2138 into a Phase 2a trial for atopic dermatitis.

Aclaris Therapeutics reports the resignation of Andrew Powell and the decision of Bryan Reasons not to seek re-election to the board of directors, both effective at the 2024 Annual Meeting.

Aclaris Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting increased revenue driven by a licensing agreement but also increased R&D expenses and a net loss.

Aclaris Therapeutics has appointed Neal Walker as Interim CEO, effective January 17, 2024, following the departure of Douglas Manion.

Aclaris Therapeutics has announced the departure of its Chief Medical Officer and CEO, along with an amended employment agreement for its Chief Scientific Officer.

Aclaris Therapeutics has announced the departure of its CEO, a new interim CEO, and a strategic review of its business.